●●○ medium
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
mPharma: Making medicine a right, not a privilege. Across much of Africa, getting medicine is a tightrope — pharmacies run out of stock, prices swing wildly, and counterfeits circulate. Gregory Rockson, a child with scoliosis, grew up watching his parents struggle to find his medicine in Ghana. In 2013, with Daniel Shoukimas and James Finucane, he founded mPharma to fix the “system,” not cure patients one by one. The model is inventory financing. mPharma buys medicine in bulk at negotiated prices from makers like Novartis and Pfizer and places it as consignment stock at small “mom-and-pop” pharmacies (they pay only for what sells, freeing their cash), tracks all inventory in the cloud, forecasts demand, and flags expirations. Using scale to lower prices, its Mutti program gives patients free membership for fixed, low prices on chronic-disease drugs, and QualityRx revives struggling pharmacies. mPharma now spans about nine countries and over 850–1,000 pharmacies and clinics, reaching over 2 million patients a year, partnering with Ghana's National Health Insurance and others. The letter is B; certainty is medium. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q2; estimate based on public information.)
Main narrative
Across much of Africa, getting medicine is a tightrope — pharmacies run out of stock, prices swing wildly, and counterfeits circulate. Gregory Rockson, a child with scoliosis, grew up watching his parents struggle to find his medicine in Ghana. In 2013, with Daniel Shoukimas and James Finucane, he founded mPharma to fix the “system,” not cure patients one by one.
The model is inventory financing. mPharma buys medicine in bulk at negotiated prices from makers like Novartis and Pfizer and places it as consignment stock at small “mom-and-pop” pharmacies (they pay only for what sells, freeing their cash), tracks all inventory in the cloud, forecasts demand, and flags expirations. Using scale to lower prices, its Mutti program gives patients free membership for fixed, low prices on chronic-disease drugs, and QualityRx revives struggling pharmacies. mPharma now spans about nine countries and over 850–1,000 pharmacies and clinics, reaching over 2 million patients a year, partnering with Ghana's National Health Insurance and others.
One person’s story (N1)
+ before → after
For a Ghanaian patient with diabetes or hypertension, finding medicine was exhausting — after visiting several pharmacies, the one in stock was out, prices varied and were high from shop to shop, and the fear of counterfeits lingered. Registering free with mPharma's Mutti, a member card lets them buy chronic-disease drugs at a fixed low price, and partner pharmacies stock steadily. Being able to keep taking medicine that's 30–60% cheaper without running out is, for a chronic patient, a literal lifeline.
Source nature: Skoll Foundation / P1 international award (Skoll). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- mPharma won the Skoll Award for Social Entrepreneurship (about $1.5 million in core support) in 2019, a major international prize for social entrepreneurs. Skoll's records report it cut drug prices by up to 30%, ended stockouts, and reduced drug-related complications by up to 25% at partner clinics. Rotary says “over 2 million people have saved on medicine costs,” and it partners with Ghana's National Health Insurance and others.P1 international award / Skoll Foundation / Rotary
− effects (confirmed)
- No confirmed −.
- Independent verification of patient outcomes; management continuity after the founder's departure; the quality of per-country expansion (Francophone, etc.); balancing the for-profit model with price restraint
A second look
Figures like “2M people,” “30–60% price cuts,” and “25% fewer complications” come mainly from company/partner reports (with some corroboration from Skoll and others), with no RCT independently verifying patient health outcomes. It is a for-profit (inventory-margin) model, and founder Gregory Rockson stepped down as CEO at the end of 2025 (to the first non-founder CEO), so continuity is a future point. Per-country regulatory, currency, and scale complexity also remains.
Sources
How to read this assessment
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q2 | Back to top